bladder cancer	presents with	hematuria
bladder cancer	presents with	dysuria
bladder cancer	presents with	urinary frequency
bladder cancer	presents with	nocturia
bladder cancer	presents with	pelvic pain
smoking	increases risk of	bladder cancer
age	increases risk of	bladder cancer
arsenic exposure	increases risk of	bladder cancer
aniline dye exposure	increases risk of	bladder cancer
cyclophosphamide exposure	increases risk of	bladder cancer
cystectomy	treats	bladder cancer
radical cystectomy	treats	bladder cancer
transurethral resection	treats	bladder tumor
intravesical therapy	treats	non-muscle-invasive bladder cancer
BCG therapy	treats	non-muscle-invasive bladder cancer
mitomycin C	treats	non-muscle-invasive bladder cancer
neoadjuvant chemotherapy	treats	muscle-invasive bladder cancer
systemic chemotherapy	treats	metastatic bladder cancer
immunotherapy	treats	bladder cancer
radiation therapy	treats	bladder cancer
urinary diversion	results from	bladder cancer surgery
urothelial carcinoma	is a histology type of	bladder cancer
carcinoma in situ	occurs with	bladder cancer
urine cytology	detects	urothelial carcinoma
urinalysis	detects	hematuria
cystoscopy	detects	bladder cancer
CT urography	detects	bladder cancer
MRI	detects	bladder cancer
PET-CT	detects	metastasis
pathology	confirms	bladder cancer
histology	identifies	urothelial carcinoma
TP53 mutation	associated with	high-grade bladder cancer
FGFR3 mutation	associated with	low-grade bladder cancer
chromosomal instability	observed in	bladder cancer
tumor stage	influences	treatment choice
TNM staging	guides	prognosis
stage IV bladder cancer	has	distant metastases
bone metastasis	occurs in	bladder cancer
liver metastasis	occurs in	bladder cancer
lung metastasis	occurs in	bladder cancer
pelvic lymph node involvement	indicates	advanced bladder cancer
recurrence	occurs after	bladder cancer treatment
surveillance cystoscopy	monitors	bladder cancer after treatment
urinary cytology	used for	bladder cancer surveillance
non-muscle-invasive bladder cancer	defined as	Ta/T1 tumors
muscle-invasive bladder cancer	defined as	T2-T4 tumors
nephrotoxicity	complication of	cisplatin therapy
cisplatin therapy	causes	nephrotoxicity
nephroureterectomy	removes	kidney and ureter
radical nephroureterectomy	removes	kidney and ureter
nephrectomy	removes	kidney
renal cell carcinoma	is a type of	kidney cancer
kidney cancer	is a cancer of	urinary tract
renal pelvis cancer	is a cancer of	renal pelvis
ureteral cancer	is a cancer of	ureter
upper urinary tract urothelial carcinoma	is a cancer of	upper urinary tract
urothelial origin	characterizes	bladder cancer
bladder cancer	prognosis depends on	stage
bladder cancer	prognosis depends on	tumor grade
tumor grade	influences	prognosis
tumor size	influences	recurrence risk
recurrence risk	increases with	incomplete resection
incomplete resection	increases	recurrence risk
surgical margins	determine	recurrence risk
multimodal therapy	used for	muscle-invasive bladder cancer
intravesical BCG therapy	induces	immune response
immune response	mediates	tumor control
PD-1 inhibitors	used for	bladder cancer
PD-L1 inhibitors	used for	bladder cancer
atezolizumab	is a	PD-L1 inhibitor
pembrolizumab	is a	PD-1 inhibitor
imaging studies	evaluate	tumor burden
tumor burden	correlates with	prognosis
microscopic hematuria	suggests	bladder cancer
gross hematuria	suggests	bladder cancer
bladder preservation	goal of	bladder cancer treatment
cystectomy	followed by	urinary diversion
salvage cystectomy	performed for	recurrent bladder cancer
urothelial carcinoma	can be	multifocal in	bladder
multifocality	common in	bladder cancer
urine cytology	negative in	low-grade urothelial carcinoma
mutational profile	guides	targeted therapy
targeted therapy	used for	bladder cancer
EGFR amplification	observed in	bladder cancer
HER2 amplification	observed in	bladder cancer
DNA methylation	altered in	bladder cancer
miRNA dysregulation	observed in	bladder cancer
weight loss	associated with	advanced bladder cancer
anemia	associated with	advanced bladder cancer
thrombocytosis	associated with	bladder cancer
paraneoplastic syndrome	rare in	bladder cancer
dysuria	symptom with	bladder cancer
therapy initiation	marks	treatment start
adjuvant therapy	used after	cystectomy
neoplasia	refers to	malignant tumor
malignant tumor	is a	cancer
neoplasm	refers to	cancer
cancer care	provided by	oncology
follow-up	includes	imaging
survival	improves with	early detection
